title: Cytotoxic T lymphocytes specific for HIV-1 gp160 antigen and synthetic P18IIIB peptide in an HLA-A11-immunized individual.
abstract: Cytotoxic T cell determinants should be an important component of an anti-human immunodeficiency virus (HIV) vaccine. The epitopes of proteins can be defined with short synthetic peptides for class I-restricted CTLs. An immunodominant CTL epitope from the HIV-1 IIIB envelope protein gp160 comprising 15 amino acids (residues 315-329: RIQRGPGRAFVTIGK) (P18IIIB) has been identified that is recognized by class I MHC molecule H-2d-restricted murine CD8+ CTLs. We have investigated the epitope specificity of anti-HIV-1 CTLs in immunized individuals and we found that the CTL response was restricted by more than one class I MHC molecule, including HLA-A2 and HLA-A3. In the present work, we also show that the response against P18IIIB peptide is restricted by the HLA-A11 molecule in an individual immunized by vaccinia virus expressing gp160 protein. This peptide could thus be recognized in association with different HLA class I allotypes. This work has implications for vaccine strategies, using the P18 peptide.
authors.affiliation: Université Pierre et Marie Curie, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Achour
authors.forename: S
authors.initials: S
authors.lastname: Lemhammedi
authors.forename: O
authors.initials: O
authors.lastname: Picard
authors.forename: J P
authors.initials: JP
authors.lastname: M'Bika
authors.forename: J F
authors.initials: JF
authors.lastname: Zagury
authors.forename: Z
authors.initials: Z
authors.lastname: Moukrim
authors.forename: A
authors.initials: A
authors.lastname: Willer
authors.forename: F
authors.initials: F
authors.lastname: Beix
authors.forename: A
authors.initials: A
authors.lastname: Burny
authors.forename: D
authors.initials: D
authors.lastname: Zagury
mesh_terms: D000595:Amino Acid Sequence; D002460:Cell Line; D015686:Gene Products, env / Q000008:administration & dosage / Q000276:immunology*; D019302:HIV Envelope Protein gp160; D015497:HIV-1 / Q000276:immunology*; D015234:HLA-A Antigens / Q000276:immunology*; D059870:HLA-A11 Antigen; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000276:immunology*; D010641:Phenotype; D011498:Protein Precursors / Q000008:administration & dosage / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014611:Vaccination
chemical_list: D015686:Gene Products, env; D019302:HIV Envelope Protein gp160; C087213:HIV-1 gp160 (315-329); D015234:HLA-A Antigens; D059870:HLA-A11 Antigen; D010446:Peptide Fragments; D011498:Protein Precursors